Edgewise Therapeutics Files 2024 10-K
Ticker: EWTX · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | 10-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Edgewise Therapeutics 2024 10-K filed: $94.8M assets, $70.5M liabilities, $13.6M equity. Boulder, CO.
AI Summary
Edgewise Therapeutics, Inc. filed its 2024 10-K on March 3, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, based in Boulder, Colorado, operates in the pharmaceutical preparations sector. Key financial data for the period includes total assets of $94.8 million and total liabilities of $70.5 million, resulting in stockholders' equity of $13.6 million.
Why It Matters
This filing provides investors with a comprehensive overview of Edgewise Therapeutics' financial health and operational status as of December 31, 2024, crucial for assessing its investment potential.
Risk Assessment
Risk Level: medium — As a company in the pharmaceutical preparations sector, Edgewise Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $94.8M — Total Assets (As of December 31, 2024)
- $70.5M — Total Liabilities (As of December 31, 2024)
- $13.6M — Stockholders' Equity (As of December 31, 2024)
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Filer of the 10-K
- March 3, 2025 (date) — Filing date of the 10-K
- December 31, 2024 (date) — Fiscal year end
- Boulder, Colorado (location) — Company headquarters
- $94.8 million (dollar_amount) — Total assets as of December 31, 2024
- $70.5 million (dollar_amount) — Total liabilities as of December 31, 2024
- $13.6 million (dollar_amount) — Stockholders' equity as of December 31, 2024
FAQ
What is the total amount of cash and cash equivalents reported by Edgewise Therapeutics as of December 31, 2024?
The filing indicates $94,838,466 in total assets, but a specific breakdown for cash and cash equivalents is not detailed in the provided snippet.
What were the total revenues for Edgewise Therapeutics for the fiscal year ending December 31, 2024?
The provided text does not contain information on total revenues for the fiscal year ending December 31, 2024.
What is the company's primary business activity as described in the 10-K?
Edgewise Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].
When was Edgewise Therapeutics, Inc. incorporated?
The company was incorporated in Delaware (DE).
What is the SEC file number for Edgewise Therapeutics, Inc.'s 10-K filing?
The SEC file number is 001-40236.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding Edgewise Therapeutics, Inc. (EWTX).